Suven Life Sciences Ltd
Suven Life Sciences is engaged in clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
- Market Cap ₹ 1,066 Cr.
- Current Price ₹ 83.8
- High / Low ₹ 109 / 19.4
- Stock P/E
- Book Value ₹ 9.20
- Dividend Yield 1.19 %
- ROCE -54.4 %
- ROE -49.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 9.11 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -52.48% over past five years.
- Company has a low return on equity of -0.22% for last 3 years.
- Debtor days have increased from 34.98 to 65.65 days.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|
192 | 90 | 2 | 2 | 2 | 1 | 3 | 9 | 1 | 9 | 2 | |
146 | 79 | 22 | 51 | 43 | 22 | 30 | 34 | 16 | 27 | 28 | |
Operating Profit | 45 | 10 | -20 | -48 | -42 | -21 | -28 | -25 | -14 | -18 | -27 |
OPM % | 24% | 11% | -936% | -2,025% | -2,635% | -1,517% | -999% | -290% | -993% | -196% | -1,762% |
Other Income | 8 | 7 | 7 | 6 | 3 | 2 | 6 | 3 | 3 | 2 | 2 |
Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 6 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 47 | 11 | -14 | -44 | -40 | -20 | -23 | -23 | -13 | -17 | -26 |
Tax % | 45% | 64% | -3% | 9% | 35% | 2% | -0% | -9% | 19% | 6% | 7% |
Net Profit | 26 | 4 | -14 | -39 | -26 | -20 | -23 | -26 | -10 | -16 | -24 |
EPS in Rs | 2.04 | 0.30 | -1.13 | -3.10 | -2.04 | -1.56 | -1.79 | -2.01 | -0.82 | -1.23 | -1.92 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
88 | 112 | 117 | 521 | 499 | 543 | 625 | 286 | 13 | 21 | |
77 | 96 | 105 | 361 | 398 | 414 | 427 | 300 | 128 | 104 | |
Operating Profit | 11 | 16 | 13 | 159 | 102 | 129 | 198 | -14 | -116 | -83 |
OPM % | 13% | 15% | 11% | 31% | 20% | 24% | 32% | -5% | -917% | -406% |
Other Income | 1 | 1 | 3 | 9 | 19 | 21 | 23 | 27 | 14 | 9 |
Interest | 2 | 3 | 5 | 5 | 6 | 6 | 5 | 2 | 1 | 1 |
Depreciation | 3 | 4 | 4 | 12 | 18 | 21 | 21 | 11 | 4 | 4 |
Profit before tax | 6 | 11 | 6 | 152 | 98 | 123 | 196 | 0 | -106 | -79 |
Tax % | 2% | -5% | -32% | 28% | 26% | 29% | 37% | 15,038% | 11% | |
Net Profit | 6 | 11 | 8 | 109 | 72 | 87 | 124 | -24 | -94 | -76 |
EPS in Rs | 0.98 | 0.72 | 8.54 | 5.64 | 6.85 | 9.72 | -1.88 | -7.40 | -5.98 | |
Dividend Payout % | 39% | 26% | 35% | 7% | 35% | 15% | 15% | -80% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -52% |
3 Years: | -71% |
TTM: | 153% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 30% |
Stock Price CAGR | |
---|---|
10 Years: | 52% |
5 Years: | 44% |
3 Years: | 87% |
1 Year: | 57% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | -0% |
Last Year: | -50% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
5 | 6 | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |
Reserves | 85 | 96 | 95 | 547 | 583 | 654 | 755 | 226 | 131 | 104 |
Borrowings | 24 | 41 | 55 | 109 | 83 | 71 | 34 | 3 | 6 | 4 |
29 | 30 | 38 | 105 | 74 | 78 | 118 | 62 | 33 | 21 | |
Total Liabilities | 143 | 173 | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 142 |
83 | 96 | 110 | 172 | 305 | 306 | 308 | 22 | 25 | 22 | |
CWIP | 3 | 5 | 4 | 107 | 7 | 10 | 25 | 0 | 0 | 3 |
Investments | 4 | 5 | 2 | 0 | 0 | 301 | 279 | 223 | 0 | 5 |
53 | 68 | 83 | 494 | 439 | 199 | 308 | 58 | 157 | 112 | |
Total Assets | 143 | 173 | 199 | 773 | 751 | 816 | 919 | 303 | 182 | 142 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
5 | 16 | 4 | 143 | 68 | 109 | 70 | -53 | -194 | |
-9 | -20 | -16 | -110 | -39 | -311 | -1 | 30 | 206 | |
3 | 13 | 6 | 179 | -68 | -30 | -52 | 5 | 3 | |
Net Cash Flow | -1 | 8 | -7 | 212 | -39 | -232 | 17 | -18 | 14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
ROCE % | 11% | 8% | 13% | 15% | 24% | -4% | -54% | ||
Debtor Days | 62 | 53 | 111 | 28 | 39 | 31 | 36 | 3 | 66 |
Inventory Turnover | 2.14 | 2.22 | 2.37 | 2.08 | 1.63 | 1.29 |
Documents
Add documentRecent announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Feb
- Announcement under Regulation 30 (LODR)-Preferential Issue 25 Feb
- Notice Of Extra-Ordinary General Meeting To Be Held On Saturday, 20Th March, 2021 25 Feb
- Outcome Of The Board Meeting Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 20 Feb
- Closure of Trading Window 17 Feb
View all
Annual reports
- Financial Year 2020 from bse
- Financial Year 2019 from bse
- Financial Year 2018 from bse
- Financial Year 2017 from bse
- Financial Year 2016 from bse
- Financial Year 2015 from bse
- Financial Year 2014 from bse
- Financial Year 2013 from bse
- Financial Year 2013 from nse
- Financial Year 2012 from bse
- Financial Year 2012 from nse
- Financial Year 2011 from bse
- Financial Year 2010 from bse
- Financial Year 2010 from nse